Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1906 to 1920 of 7708 results

  1. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  2. Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257

    In development [GID-TA11071] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  4. Suspected cancer update

    In development [GID-QS10176] Expected publication date: TBC

    Quality standard
    In development

  5. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]

    Awaiting development [GID-TA10791] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015

    Awaiting development [GID-TA11551] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895

      Status ...

    Technology appraisal guidance
    Topic selection

  10. The MIST Therapy system for the promotion of wound healing (MTG5)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG5

  11. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (DG5)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver

    Diagnostics guidance
    Published
    29 August 2012
    View recommendations

    Sections for DG5

  12. Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    Medical technologies guidance
    Published
    25 July 2011
    View recommendations

    Sections for MTG6

  13. Spinal instrumentation with robot assisted navigation

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  14. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years TSID 12002

      Status ...

    Technology appraisal guidance
    Topic selection

  15. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (MTG2)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

    Medical technologies guidance
    Last updated
    7 August 2017
    View recommendations

    Sections for MTG2